IN8bio (NASDAQ:INAB – Free Report) had its target price lowered by HC Wainwright from $8.00 to $6.00 in a report issued on Friday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock.
IN8bio Stock Performance
Shares of INAB stock opened at $0.23 on Friday. The stock has a market cap of $18.32 million, a P/E ratio of -0.30 and a beta of 0.03. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.84 and a quick ratio of 1.84. The company has a fifty day moving average price of $0.28 and a two-hundred day moving average price of $0.30. IN8bio has a one year low of $0.21 and a one year high of $1.74.
IN8bio (NASDAQ:INAB – Get Free Report) last announced its earnings results on Thursday, March 13th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.03. As a group, equities analysts predict that IN8bio will post -0.56 EPS for the current year.
Institutional Trading of IN8bio
About IN8bio
IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.
Featured Stories
- Five stocks we like better than IN8bio
- How to Calculate Options Profits
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- Profitably Trade Stocks at 52-Week Highs
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- What is a Dividend King?
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Receive News & Ratings for IN8bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IN8bio and related companies with MarketBeat.com's FREE daily email newsletter.